What We Know About Stage II and III Colon Cancer: It's Still Not Enough.

Puccini, Alberto; Berger, Martin Dave; Zhang, Wu; Lenz, Heinz-Josef (2017). What We Know About Stage II and III Colon Cancer: It's Still Not Enough. Targeted oncology, 12(3), pp. 265-275. Springer 10.1007/s11523-017-0494-5

[img]
Preview
Text
Puccini2017_Article_WhatWeKnowAboutStageIIAndIIICo.pdf - Published Version
Available under License Publisher holds Copyright.

Download (435kB) | Preview

The introduction of oxaliplatin as adjuvant treatment for stage III colon cancer in 2004 has been the last practice changing progress in adjuvant treatment for patients with early colon cancer. Since then, many prognostic and predictive biomarkers have been studied, but only DNA mismatch repair status has been validated as having an important prognostic value. Accordingly, TNM and clinical-pathological patterns, such as pT4 lesions and lymph node sampling <12 nodes, are the main factors that guide physicians' choice regarding adjuvant treatment. More recently, many biomarkers showed promising results: POLE, ErbB2, CDX2, SMAD4, BRAF and KRAS. In addition to these, immune-contexture, molecular classification, and gene signatures could become new ways to better classify colon cancer patients with more discriminatory power than TNM. The aim of this review is to report the state-of-the-art of prognostic and predictive factors in the adjuvant setting and which of these could modify clinical practice and maybe replace TNM classification.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Berger, Martin Dave

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1776-2596

Publisher:

Springer

Language:

English

Submitter:

Nicole Corminboeuf

Date Deposited:

12 Jul 2018 11:03

Last Modified:

16 May 2021 02:30

Publisher DOI:

10.1007/s11523-017-0494-5

PubMed ID:

28504299

BORIS DOI:

10.7892/boris.111403

URI:

https://boris.unibe.ch/id/eprint/111403

Actions (login required)

Edit item Edit item
Provide Feedback